EyePoint (EYPT) Operating Income (2010 - 2026)
EyePoint (EYPT) reported Operating Income of -$87.2 million for Q1 2026, down 78.61% on a YoY basis from -$407.7 million in Q1 2025, and down 24.0% sequentially from -$70.3 million in Q4 2025.
EyePoint (EYPT) Operating Income (2010 - 2026) Analysis & Trends
EyePoint (EYPT) has 17 years of Operating Income data on file, last reported at -$87.2 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income fell 78.61% year-over-year to -$87.2 million; the trailing twelve-month figure through Mar 2026 stood at -$281.8 million (down 74.64% YoY), and the FY2025 full-year result was -$243.4 million, down 66.9% from the prior year.
- Operating Income slipped to -$87.2 million in Q1 2026, from -$70.3 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$14.4 million in Q3 2023 to a low of -$87.2 million in Q1 2026.
- A 5-year average of -$38.3 million and a median of -$33.3 million in 2024 frame the typical range for Operating Income.
- Across the five-year window, Operating Income surged 62.61% in 2023 and plunged 176.62% in 2024, its largest moves.
- Tracing EYPT's Operating Income over 5 years: stood at -$43.7 million in 2022, then surged by 62.61% to -$16.4 million in 2023, then plunged by 176.62% to -$45.2 million in 2024, then slumped by 55.5% to -$70.3 million in 2025, then decreased by 24.0% to -$87.2 million in 2026.
- Business Quant data shows EYPT's Operating Income at -$87.2 million in Q1 2026, -$70.3 million in Q4 2025, and -$62.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | EyePoint | 358.61 Mn | 136.07 Mn | 168,000.00 | -87.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -87.23 Mn |
| Dec 31, 2025 | -70.35 Mn |
| Sep 30, 2025 | -62.03 Mn |
| Jun 30, 2025 | -62.23 Mn |
| Mar 31, 2025 | -48.84 Mn |
| Dec 31, 2024 | -45.24 Mn |
| Sep 30, 2024 | -32.75 Mn |
| Jun 30, 2024 | -34.55 Mn |
| Mar 31, 2024 | -33.32 Mn |
| Dec 31, 2023 | -16.35 Mn |
| Sep 30, 2023 | -14.40 Mn |
| Jun 30, 2023 | -22.76 Mn |
| Mar 31, 2023 | -21.55 Mn |
| Dec 31, 2022 | -43.74 Mn |
| Sep 30, 2022 | -18.40 Mn |
| Jun 30, 2022 | -19.22 Mn |
| Mar 31, 2022 | -18.28 Mn |
| Dec 31, 2021 | -18.05 Mn |
| Sep 30, 2021 | -15.31 Mn |
| Jun 30, 2021 | -10.98 Mn |